查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1782004

胃肠治疗市场，按药物类型、按药物类型、按剂型、按应用、按配销通路、按国家/地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Gastrointestinal Therapeutics Market, By Medication Type, By Drug Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 284 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年胃肠治疗市场规模价值 402.0911 亿美元，2025 年至 2032 年期间的复合年增长率为 5.50%。

胃肠治疗市场-市场动态

生物製剂的进步提高了治疗效果和采用率

生物製剂的进步带来了更具针对性和有效性的疗法，彻底改变了胃肠道疾病的治疗方式。这些疗法透过特异性调节免疫系统发挥作用，从而比传统药物更有效地控制发炎和症状。艾伯维的修美乐（阿达木单抗）是一种广泛用于治疗克罗恩病和溃疡性结肠炎的生物製剂，其标靶疗法显着改善了患者的预后，充分体现了生物製剂的成功。生物相似药的推出进一步促进了生物製剂的成长，使其更易于获取且价格更亲民，从而推动了胃肠道治疗市场对生物製剂的整体应用。

例如，

2024年3月，辉瑞推出了热门生物製剂的生物相似药，扩大了在胃肠道治疗市场的份额。这些生物相似药的疗效和安全性与原厂生物製剂相当，但成本更低，使更广泛的患者群体，尤其是在成本敏感的市场，更容易获得先进的治疗方案。

2023年9月，强生公司推出了旨在治疗发炎性肠道疾病的创新生物疗法。他们的新产品专注于针对特定的免疫途径，以更有效地减轻炎症，为患者提供可能改善长期疾病管理和疗效的新选择。

这些持续的创新和生物製剂的扩大应用预计将推动胃肠道治疗市场的显着增长和患者治疗效果的改善。

胃肠治疗市场—关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 5.50%。

根据药物类型细分，预计品牌药物将在 2024 年占据最大市场份额

根据药物类型细分，生物製剂/生物相似药是 2024 年的主要药物类型

根据剂型细分，口服是 2024 年的主要剂型

根据应用细分，胃食道逆流症 (GERD) 是 2024 年的主要应用

根据配销通路细分，医院药房是2024年的主要配销通路

按地区划分，北美是 2024 年的主要收入来源

胃肠治疗市场-細項分析：

全球胃肠治疗市场根据药物类型、药物类型、剂型、应用、配销通路和地区进行细分。

根据药物类型，市场分为两类：品牌药和仿製药。品牌药领域占市场主导地位。这得益于医生对成熟且经过临床验证的药物的强烈偏好，积极的市场营销和品牌认知度推动了仿製药的高采用率，以及针对克罗恩病、溃疡性结肠炎和肠易激综合征等复杂胃肠道疾病的创新製剂的供应。此外，专利保护和监管排他性限制了仿製药在某些治疗领域的渗透，尤其是在对先进和专业治疗需求更高的已开发地区。

根据应用，市场分为五类：克隆氏症、胃食道逆流症 (GERD)、肠躁症 (IBS)、溃疡性结肠炎等。胃食道逆流症 (GERD) 是胃肠道治疗市场的主要应用领域。这主要归因于其全球盛行率高，尤其是在已开发地区，以及该疾病的慢性性质，通常需要长期或终身治疗。质子帮浦抑制剂 (PPI) 和 H2 受体拮抗剂的广泛使用，再加上肥胖、不良饮食和压力等生活方式相关因素导致的诊断率上升，进一步增强了 GERD 在该市场的主导地位。此外，强大的药物管道和针对 GERD 的持续产品创新为其领先的市场份额做出了重要贡献。

胃肠治疗市场—地理洞察

在 2024 年的预测期内，北美将主导全球胃肠治疗市场。

北美引领胃肠道治疗市场，凭藉其先进的医疗基础设施和高昂的医疗支出占据最大份额。该地区胃肠道疾病（例如胃食道逆流症 (GERD)、肠躁症 (IBS) 和克隆氏症）的发生率较高，因此对有效疗法的需求强劲。大型製药公司的布局、完善的监管框架以及创新药物的广泛可及性进一步促进了市场成长。较高的认知度、早期诊断和优惠的报销政策也巩固了该地区的主导地位。美国是北美市场的主要驱动力，得益于持续的研发投入和新型治疗方案的快速应用。

预计在 2024 年的预测期内，亚太地区的胃肠治疗市场复合年增长率最高。

亚太地区是胃肠道治疗市场成长最快的地区，其驱动力源自于人口规模庞大且老化加剧，胃肠道疾病的盛行率也随之上升。快速的城市化、生活方式的改变以及饮食结构的转变，导致胃食道逆流症 (GERD) 和肠躁症 (IBS) 等疾病的发生率上升。不断增长的医疗保健投资、政府倡议以及医疗服务可近性的不断扩大，正在推动中国、印度和韩国等国家市场的发展。由于该地区尚未开发的潜力以及对价格实惠、高品质治疗药物日益增长的需求，製药公司越来越关注该地区。认知度的提高和医疗保健基础设施的完善，正在进一步加速该地区的成长。

胃肠治疗市场-竞争格局：

胃肠道治疗市场竞争激烈，许多全球及地区性企业积极参与创新疗法的研发与商业化。艾伯维公司、武田製药有限公司、强生公司、辉瑞公司和阿斯特捷利康等主要公司凭藉强大的产品组合占据市场主导地位，这些产品组合针对克罗恩病、溃疡性结肠炎、胃食道逆流（GERD）和肠躁症（IBS）等主要胃肠道疾病。这些企业专注于策略合作、併购和广泛的研发，以维持市场地位并扩展其治疗产品。

同时，大量新兴生技公司纷纷进军此领域，致力于研发疗效更佳、安全性更高的尖端生物製剂及小分子药物。生物相似药和仿製药的日益普及也加剧了价格竞争，尤其是在发展中市场。各大公司正投入资源，扩大全球影响力，争取监管部门的批准，并推出先进的给药系统，以维持领先地位。简而言之，创新、强大的产品线和地理扩张是塑造该市场竞争格局的驱动力。

最新动态：

2025年2月，Zydus Lifesciences获得美国FDA核准生产布洛芬和法莫替丁锭剂。这些片剂旨在治疗类风湿性关节炎和骨关节炎，同时降低上消化道溃疡的风险。此项批准旨在扩大Zydus的消化道产品组合，以减轻消化性溃疡患者的负担。

2025年4月，艾尔建公司完成了对Viral Burn的收购。 Viral Burn是一家专注于开发新型胃肠道疾病疗法的私人生物技术公司。此次收购将Viral Burn的主导产品VB-201纳入艾尔建的产品线。 VB-201是一种用于治疗诺罗病毒性胃肠炎的首创口服非全身性抗病毒疗法。

2021年4月，梯瓦製药美国公司（Teva Pharmaceuticals USA）在美国推出了其1000毫克Casana（美沙拉嗪）栓剂仿製药，用于治疗活动性溃疡性直肠炎成人患者。这款价格实惠的仿製药的推出提高了治疗的可及性，并透过提供经济高效的选择，使梯瓦在胃肠道疾病市场占据了强势地位。此外，随着溃疡性结肠炎盛行率不断上升，该仿製药也有助于公司抓住这一机会，并抓住治疗需求不断增长的机会。

目录

第一章：胃肠治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 胃肠治疗市场（按药物类型）
    • 胃肠治疗市场（按药物类型）
    • 胃肠治疗市场（按剂型）摘要
    • 胃肠治疗市场片段（按应用）
    • 胃肠治疗市场按配销通路划分
    • 胃肠治疗市场（按国家/地区）
    • 胃肠治疗市场（按地区）
  • 竞争洞察

第三章：胃肠治疗关键市场趋势

  • 胃肠治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 胃肠道治疗市场限制
    • 市场限制的影响分析
  • 胃肠治疗市场机会
  • 胃肠治疗市场未来趋势

第四章：胃肠治疗产业研究

  • PESTEL分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：胃肠治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：胃肠治疗市场格局

  • 2024年胃肠治疗市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：胃肠治疗市场－依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 品牌
    • 泛型

第 8 章：胃肠道治疗市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 抗酸药
    • 止吐药
    • 止泻药
    • 抗溃疡药
    • 抗生素
    • 生物製剂/生物相似药
    • 泻药
    • 质子帮浦抑制剂（PPI）
    • 其他药物类型

第九章：胃肠治疗市场－按剂型

  • 概述
    • 按剂型分類的细分市场份额分析
    • 口服
    • 肠外

第 10 章：胃肠治疗市场 - 按应用

  • 概述
    • 按应用细分市场占有率分析
    • 克罗恩病
    • 胃食道逆流症（GERD）
    • 肠躁症（IBS）
    • 溃疡性结肠炎
    • 其他的

第 11 章：胃肠治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 12 章：胃肠治疗市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美胃肠治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按药物类型）
    • 北美市场规模及预测（依药品类型）
    • 北美市场规模及预测（按剂型）
    • 北美市场规模和预测（按应用）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲胃肠治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按药物类型）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（按剂型）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区胃肠治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依药物类型）
    • 亚太地区市场规模及预测（依药品类型）
    • 亚太地区市场规模及预测（依剂型划分）
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲胃肠治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按药物类型）
    • 拉丁美洲市场规模及预测（按药物类型）
    • 拉丁美洲市场规模及预测（以剂型划分）
    • 拉丁美洲市场规模及预测（按应用）
    • LATAM 规模及预测（依配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲胃肠治疗主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（依药品类型）
    • 中东和非洲市场规模及预测（按剂型）
    • 中东和非洲市场规模和预测（按应用）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：胃肠治疗产业主要供应商分析

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corp.
    • Cipla
    • Eisai Co. Ltd.
    • Eli Lilly and Co.
    • Evoke Pharma Inc.
    • GlaxoSmithKline Plc
    • Johnson and Johnson Services Inc.
    • Merck and Co. Inc.
    • Novartis AG
    • Olympus Corp.
    • Ovesco Endoscopy AG
    • Pfizer Inc.
    • Salix Pharmaceuticals Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • UCB SA
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5444

REPORT HIGHLIGHT

Gastrointestinal Therapeutics Market size was valued at US$ 40,209.11 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.

The Gastrointestinal Therapeutics Market is all about producing, and distributing medications aimed at tackling issues related to the digestive system. This includes a variety of conditions like Crohn's disease, ulcerative colitis, GERD, IBS, and various infections that can affect the gastrointestinal (GI) tract. The market features a broad spectrum of treatments, such as antacids, biologics, anti-diarrheal, proton pump inhibitors, laxatives, and antibiotics, which can be administered through both oral and injectable forms. The growing demand in this sector is largely fueled by the increasing rates of GI diseases, lifestyle related digestive problems, and the latest advancements in targeted therapies and biologics. Both branded and generic medications play a role in this market, which is primarily supplied through hospitals, retail outlets, and online pharmacies.

Gastrointestinal Therapeutics Market- Market Dynamics

Advancements in biologics enhance therapeutic effectiveness and adoption

Advancements in biologics have transformed the treatment of gastrointestinal disorders by offering more targeted and effective therapies. These treatments work by specifically modulating the immune system, which helps control inflammation and manage symptoms better than traditional drugs. AbbVie's Humira (adalimumab), a biologic drug widely used for Crohn's disease and ulcerative colitis, exemplifies this success with its targeted approach significantly improving patient outcomes. The introduction of biosimilar versions has further supported this growth by making these therapies more accessible and affordable, boosting the overall adoption of biologic therapies in the gastrointestinal therapeutics market.

for instance,

In March 2024, Pfizer expanded its presence in the GI therapeutics market by launching biosimilar versions of popular biologics. These biosimilars offer comparable efficacy and safety to original biologics but at a lower cost, making advanced treatments more accessible to a wider patient population, especially in cost sensitive markets.

In September 2023, Johnson & Johnson introduced innovative biologic therapies aimed at treating inflammatory bowel diseases. Their new products focus on targeting specific immune pathways to reduce inflammation more effectively, providing patients with new options that could potentially improve long-term disease management and outcomes.

These continuous innovations and expanded access to biologics are expected to drive significant growth and improved patient outcomes in the gastrointestinal therapeutics market.

Gastrointestinal Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2025-2032)

Based on medication type segmentation, branded was predicted to show maximum market share in the year 2024

Based on drug type segmentation, biologics/ biosimilars was the leading drug type in 2024

Based on dosage form segmentation, oral was the leading dosage form in 2024

Based on application segmentation, gastroesophageal reflux disease (GERD) was the leading application in 2024

Based on distribution channel segmentation, hospital pharmacies was the leading distribution channel in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gastrointestinal Therapeutics Market- Segmentation Analysis:

The global gastrointestinal therapeutics market is segmented on the basis of medication type, drug type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on medication type: Branded, and Generics. The Branded sector dominates the market. Due to strong physician preference for established, clinically validated drugs, high adoption driven by aggressive marketing and brand recognition, and the availability of innovative formulations targeting complex GI conditions such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Additionally, patent protections and regulatory exclusivity have limited the penetration of generics in certain therapeutic segments, especially in developed regions where there is a higher demand for advanced and specialized treatments.

The market is divided into five categories based on application: crohn's disease, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), ulcerative colitis, others. Gastroesophageal Reflux Disease (GERD) represents the dominating application segment in the gastrointestinal therapeutics market. This is largely attributed to its high global prevalence, especially in developed regions, and the chronic nature of the condition, which often requires long-term or lifelong management. The widespread use of proton pump inhibitors (PPIs) and H2 receptor antagonists, coupled with increasing diagnosis rates due to lifestyle-related factors such as obesity, poor diet, and stress, further fuels the dominance of GERD in this market. Additionally, strong pharmaceutical pipelines and continuous product innovation targeting GERD contribute significantly to its leading market share.

Gastrointestinal Therapeutics Market- Geographical Insights

North America dominates the global gastrointestinal therapeutics market during the forecast period in 2024.

North America leads the gastrointestinal therapeutics market, accounting for the largest share due to its advanced healthcare infrastructure and high healthcare spending. The region experiences a significant burden of gastrointestinal disorders such as GERD, IBS, and Crohn's disease, which drives strong demand for effective therapies. The presence of major pharmaceutical companies, a well-established regulatory framework, and widespread access to innovative drugs further enhance market growth. High awareness levels, early diagnosis, and favourable reimbursement policies also contribute to the region's dominance. The United States is the primary driver within North America, supported by ongoing R&D investments and rapid adoption of novel treatment options.

Asia Pacific is estimated to register the highest CAGR in the gastrointestinal therapeutics market during the forecast period in 2024.

Asia-Pacific is the fastest growing region in the gastrointestinal therapeutics market, driven by a large and aging population with increasing prevalence of GI disorders. Rapid urbanization, lifestyle changes, and dietary shifts are contributing to a higher incidence of diseases such as GERD and IBS. Growing healthcare investments, government initiatives, and expanding access to medical care are supporting market development across countries like China, India, and South Korea. Pharmaceutical companies are increasingly focusing on this region due to its untapped potential and rising demand for affordable, high-quality therapeutics. Improved awareness and healthcare infrastructure are further accelerating growth across the region.

Gastrointestinal Therapeutics Market- Competitive Landscape:

The gastrointestinal therapeutics market is highly competitive, with the presence of several global and regional players actively engaged in research, development, and commercialization of innovative treatments. Key companies such as AbbVie Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Pfizer Inc., and AstraZeneca dominate the market with strong product portfolios targeting major GI disorders like Crohn's disease, ulcerative colitis, GERD, and IBS. These players focus on strategic collaborations, mergers & acquisitions, and extensive R&D to maintain their market positions and expand their therapeutic offerings.

At the same time, there's a surge of emerging biotech firms stepping into the ring, working on cutting-edge biologics and small molecules that promise better efficacy and safety. The growing presence of biosimilars and generic drugs is also ramping up price competition, especially in developing markets. Companies are pouring resources into expanding their global reach, securing regulatory approvals, and rolling out advanced drug delivery systems to stay ahead of the game. In a nutshell, innovation, a strong pipeline, and geographic expansion are the driving forces shaping the competitive landscape of this market.

Recent Developments:

In February 2025, Zydus Lifesciences received U.S. FDA approval for the production Ibuprofen and Famotidine tablets. These tablets were designed to treat rheumatoid arthritis and osteoarthritis while reducing the risk of upper GI ulcers. This approval aimed to broaden Zydus's GI portfolio addressing the burden of peptic ulcer cases

In April 2025, Allergan plc completed the acquisition of Viral Burn, a privately-held biotechnology company focused on developing novel therapeutics for gastrointestinal diseases. The acquisition adds Viral Burn's lead asset, VB-201, a first in class, oral, non-systemic antiviral therapy for the treatment of norovirus gastroenteritis, to Allergan's pipeline

In April 2021, Teva Pharmaceuticals USA launched its 1000 mg generic version of Casana (mesalamine) suppository for treating adults with active ulcerative proctitis in the U.S. The introduction of this affordable generic alternative increases treatment accessibility and positions Teva strongly in the GI market by offering cost-effective options. It also helps the company capitalize on the growing demand for ulcerative colitis treatments amid rising prevalence

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corp.
  • Cipla
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Evoke Pharma Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Olympus Corp.
  • Ovesco Endoscopy AG
  • Pfizer Inc.
  • Salix Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generics

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antacids
  • Antiemetics
  • Antidiarrheals
  • Antiulcer agents
  • Antibiotics
  • Biologics/ biosimilars
  • Laxatives
  • Proton pump inhibitors (PPIs)
  • Other drug types

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Crohn's disease
  • Gastroesophageal reflux disease (GERD)
  • Irritable Bowel Syndrome (IBS)
  • Ulcerative colitis
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastrointestinal Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastrointestinal Therapeutics Market Snippet by Medication Type
    • 2.1.2. Gastrointestinal Therapeutics Market Snippet by Drug Type
    • 2.1.3. Gastrointestinal Therapeutics Market Snippet by Dosage Form
    • 2.1.4. Gastrointestinal Therapeutics Market Snippet by Application
    • 2.1.5. Gastrointestinal Therapeutics Market Snippet by Distribution Channel
    • 2.1.6. Gastrointestinal Therapeutics Market Snippet by Country
    • 2.1.7. Gastrointestinal Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastrointestinal Therapeutics Key Market Trends

  • 3.1. Gastrointestinal Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastrointestinal Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastrointestinal Therapeutics Market Opportunities
  • 3.4. Gastrointestinal Therapeutics Market Future Trends

4. Gastrointestinal Therapeutics Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastrointestinal Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastrointestinal Therapeutics Market Landscape

  • 6.1. Gastrointestinal Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastrointestinal Therapeutics Market - By Medication Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Medication Type, 2024 & 2032 (%)
    • 7.1.2. Branded
    • 7.1.3. Generics

8. Gastrointestinal Therapeutics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 8.1.2. Antacids
    • 8.1.3. Antiemetics
    • 8.1.4. Antidiarrheals
    • 8.1.5. Antiulcer agents
    • 8.1.6. Antibiotics
    • 8.1.7. Biologics/ biosimilars
    • 8.1.8. Laxatives
    • 8.1.9. Proton pump inhibitors (PPIs)
    • 8.1.10. Other drug types

9. Gastrointestinal Therapeutics Market - By Dosage Form

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Gastrointestinal Therapeutics Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Crohn's disease
    • 10.1.3. Gastroesophageal reflux disease (GERD)
    • 10.1.4. Irritable Bowel Syndrome (IBS)
    • 10.1.5. Ulcerative colitis
    • 10.1.6. Others

11. Gastrointestinal Therapeutics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies

12. Gastrointestinal Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastrointestinal Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastrointestinal Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastrointestinal Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Gastrointestinal Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastrointestinal Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastrointestinal Therapeutics Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Abbott Laboratories
    • 13.2.2. AbbVie Inc.
    • 13.2.3. AstraZeneca Plc
    • 13.2.4. Bayer AG
    • 13.2.5. Biogen Inc.
    • 13.2.6. Boehringer Ingelheim International GmbH
    • 13.2.7. Boston Scientific Corp.
    • 13.2.8. Cipla
    • 13.2.9. Eisai Co. Ltd.
    • 13.2.10. Eli Lilly and Co.
    • 13.2.11. Evoke Pharma Inc.
    • 13.2.12. GlaxoSmithKline Plc
    • 13.2.13. Johnson and Johnson Services Inc.
    • 13.2.14. Merck and Co. Inc.
    • 13.2.15. Novartis AG
    • 13.2.16. Olympus Corp.
    • 13.2.17. Ovesco Endoscopy AG
    • 13.2.18. Pfizer Inc.
    • 13.2.19. Salix Pharmaceuticals Inc.
    • 13.2.20. Takeda Pharmaceutical Co. Ltd.
    • 13.2.21. UCB SA
    • 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us